A single molecule agonising two incretin receptors. Tirzepatide is built on a GIP-analog backbone with balanced GLP-1 receptor activity, producing insulinotropic effects through both pathways. GIP receptor engagement in adipose tissue and the CNS appears to contribute effects distinct from GLP-1 alone, though the relative contribution of each arm remains an active research question.
The SURPASS programme in type 2 diabetes and SURMOUNT programme in obesity demonstrated glycaemic and weight outcomes that generally exceeded GLP-1 monotherapy comparators in head-to-head and cross-trial comparison. Additional approval followed for obstructive sleep apnoea in obesity.
FDA-approved for type 2 diabetes and chronic weight management, with an additional indication in obstructive sleep apnoea. Prescription-only.
Boxed warning for rodent thyroid C-cell tumours; same MTC/MEN2 contraindication as GLP-1 agents. Gastrointestinal adverse effects are dose-limiting for many patients. Physician supervision required.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.